Tumor DNA test may match patients to smarter cancer drugs
NCT ID NCT02342158
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic changes that could be treated with existing drugs. The goal was to see how often this approach leads to a personalized treatment plan.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could show that routine genetic testing of tumors helps doctors choose more effective, personalized treatments for advanced cancer.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures how often a genetic target is found, not whether the matched therapy actually works or improves survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Paoli-Calmettes
Marseille, 13009, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?